Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138927 | 1.00 | SLC1A3 (0.61) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL2141425 | 1.00 | SLC1A3 (0.61) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL2142681 | 0.92 | HTT (0.62) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL2142677 | 0.92 | HTT (0.62) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL2141943 | 0.91 | FOLH1 (0.61) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL2141938 | 0.91 | FOLH1 (0.61) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL13902998 | 0.86 | LMNA (0.54) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL11455100 | 0.85 | SLC1A3 (0.57) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL1336737 | 0.84 | SLC1A3 (0.56) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL1336735 | 0.84 | SLC1A3 (0.56) | SLC1A3SLC1A1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486753-B1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4486753-A1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | Revagenix, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023166488-A1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20160152653-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | MEIJI SEIKA PHARMA CO LTD (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260465-B2 | Aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| CN-102942603-B | New aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| EP-2036917-B1 | NOVEL AMINOGLYCOSIDE ANTIBIOTIC | MEIJI SEIKA PHARMA CO LTD (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20130345411-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-12-26 | — | — | US | disclosed |
| US-8541394-B2 | Aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20120165283-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | KOBAYASHI YOSHIHIKO (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8148504-B2 | Aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20090186841-A1 | Novel aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2036917-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTIC | MEIJI SEIKA KAISHA LTD. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345411-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | SLC1A3 3337/4885SLC1A1 3124/4885LMNA 2792/4885 |
| US-20120165283-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | SLC1A3 3337/4885SLC1A1 3124/4885LMNA 2792/4885 |
| US-20160152653-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | SLC1A3 3337/4885SLC1A1 3124/4885LMNA 2792/4885 |
| US-20090186841-A1 | Novel aminoglycoside antibiotics | ATP6V1B1, REN, NRDC | SLC1A3 3337/4885SLC1A1 3124/4885LMNA 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.